Effect of transcription peptide inhibitors on HIV-1 replication

Virology

Volumn 376, Issue 2, 2008, Pages 308-322

  Van Duyne, Rachel ^a   Cardenas, Jessica ^a   Easley, Rebecca ^a   Wu, Weilin ^a   Kehn Hall, Kylene ^a   Klase, Zak ^a   Mendez, Susana ^b   Zeng, Chen ^c   Chen, Hao ^c   Saifuddin, Mohammed ^d   Kashanchi, Fatah ^a,e,f  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e J CRAIG VENTER INSTITUTE   (United States)

^f WM Keck Institute for Proteomics Technology and Applications   (United States)

Author keywords

Cell cycle; Computer modeling; Cyclin dependent kinase; HIV; PBMC; Peptide inhibitor; Small animal model; Stem cells; Tat; Transcription

Indexed keywords

CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; PHOSPHOTRANSFERASE; PROTEIN INHIBITOR; TAT PEPTIDE INHIBITOR; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CELL CYCLE; COMPLEX FORMATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CELL LINE; CYCLIN-DEPENDENT KINASE 2; DNA-BINDING PROTEINS; FEMALE; GAMMA-CRYSTALLINS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; RUMEX;

EID: 44649186124     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.02.036     Document Type: Article

References (56)

1. Agbottah E., de la Fuente C., Nekhai S., Barnett A., Gianella-Borradori A., Pumfery A., and Kashanchi F. Antiviral activity of CYC202 in HIV-1-infected cells. J. Biol. Chem. 280 4 (2005) 3029-3042
2. Agbottah E., Zhang N., Dadgar S., Pumfery A., Wade J.D., Zeng C., and Kashanchi F. Inhibition of HIV-1 virus replication using small soluble Tat peptides. Virology 345 2 (2006) 373-389
3. Ammosova T., Berro R., Kashanchi F., and Nekhai S. RNA interference directed to CDK2 inhibits HIV-1 transcription. Virology 341 2 (2005) 171-178
4. Ammosova T., Berro R., Jerebtsova M., Jackson A., Charles S., Klase Z., Southerland W., Gordeuk V.R., Kashanchi F., and Nekhai S. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 3 (2006) 78
5. Athanassiou Z., Dias R.L., Moehle K., Dobson N., Varani G., and Robinson J.A. Structural mimicry of retroviral tat proteins by constrained beta-hairpin peptidomimetics: ligands with high affinity and selectivity for viral TAR RNA regulatory elements. J. Am. Chem. Soc. 126 22 (2004) 6906-6913
6. Baenziger S., Tussiwand R., Schlaepfer E., Mazzucchelli L., Heikenwalder M., Kurrer M.O., Behnke S., Frey J., Oxenius A., Joller H., Aguzzi A., Manz M.G., and Speck R.F. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc. Natl. Acad. Sci. U. S. A. 103 43 (2006) 15951-15956
7. Berges B.K., Wheat W.H., Palmer B.E., Connick E., and Akkina R. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model. Retrovirology 3 (2006) 76
8. Bieniasz P.D., Grdina T.A., Bogerd H.P., and Cullen B.R. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc. Natl. Acad. Sci. U. S. A. 96 14 (1999) 7791-7796
9. Bohan C.A., Kashanchi F., Ensoli B., Buonaguro L., Boris-Lawrie K.A., and Brady J.N. Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr. 2 4 (1992) 391-407
10. Boulanger M.C., Liang C., Russell R.S., Lin R., Bedford M.T., Wainberg M.A., and Richard S. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J. Virol. 79 1 (2005) 124-131
11. Brady J., and Kashanchi F. Tat gets the "green" light on transcription initiation. Retrovirology 2 (2005) 69
12. Bres V., Tagami H., Peloponese J.M., Loret E., Jeang K.T., Nakatani Y., Emiliani S., Benkirane M., and Kiernan R.E. Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF. EMBO J. 21 24 (2002) 6811-6819
13. Bres V., Kiernan R.E., Linares L.K., Chable-Bessia C., Plechakova O., Treand C., Emiliani S., Peloponese J.M., Jeang K.T., Coux O., Scheffner M., and Benkirane M. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat. Cell Biol. 5 8 (2003) 754-761
14. Chiang C.M., and Roeder R.G. Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators. Science 267 5197 (1995) 531-536
15. Christensen H.S., Daher A., Soye K.J., Frankel L.B., Alexander M.R., Laine S., Bannwarth S., Ong C.L., Chung S.W., Campbell S.M., Purcell D.F., and Gatignol A. Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production. J. Virol. 81 10 (2007) 5121-5131
16. Dal Monte P., Landini M.P., Sinclair J., Virelizier J.L., and Michelson S. TAR and Sp1-independent transactivation of HIV long terminal repeat by the Tat protein in the presence of human cytomegalovirus IE1/IE2. Aids 11 3 (1997) 297-303
17. Deng L., de la Fuente C., Fu P., Wang L., Donnelly R., Wade J.D., Lambert P., Li H., Lee C.G., and Kashanchi F. Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 277 2 (2000) 278-295
18. Deng L., Wang D., de la Fuente C., Wang L., Li H., Lee C.G., Donnelly R., Wade J.D., Lambert P., and Kashanchi F. Enhancement of the p300 HAT activity by HIV-1 Tat on chromatin DNA. Virology 289 2 (2001) 312-326
19. Deng L., Ammosova T., Pumfery A., Kashanchi F., and Nekhai S. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J. Biol. Chem. 277 37 (2002) 33922-33929
20. Feinberg M.B., Baltimore D., and Frankel A.D. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc. Natl. Acad. Sci. U. S. A. 88 9 (1991) 4045-4049
21. Garcia-Martinez L.F., Ivanov D., and Gaynor R.B. Association of Tat with purified HIV-1 and HIV-2 transcription preinitiation complexes. J. Biol. Chem. 272 11 (1997) 6951-6958
22. Gorantla S., Sneller H., Walters L., Sharp J.G., Pirruccello S.J., West J.T., Wood C., Dewhurst S., Gendelman H.E., and Poluektova L. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J. Virol. 81 6 (2007) 2700-2712
23. Herrmann C.H., and Rice A.P. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69 3 (1995) 1612-1620
24. Herrmann C.H., and Mancini M.A. The Cdk9 and cyclin T subunits of TAK/P-TEFb localize to splicing factor-rich nuclear speckle regions. J. Cell Sci. 114 Pt 8 (2001) 1491-1503
25. Jacque J.M., Triques K., and Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 418 6896 (2002) 435-438
26. Jalota-Badhwar A., Kaul-Ghanekar R., Mogare D., Boppana R., Paknikar K.M., and Chattopadhyay S. SMAR1-derived P44 peptide retains its tumor suppressor function through modulation of p53. J. Biol. Chem. 282 13 (2007) 9902-9913
27. Jeang K.T., Chun R., Lin N.H., Gatignol A., Glabe C.G., and Fan H. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J. Virol. 67 10 (1993) 6224-6233
28. Kashanchi F., Agbottah E.T., Pise-Masison C.A., Mahieux R., Duvall J., Kumar A., and Brady J.N. Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator. J. Virol. 74 2 (2000) 652-660
29. Kashanchi F., Piras G., Radonovich M.F., Duvall J.F., Fattaey A., Chiang C.M., Roeder R.G., and Brady J.N. Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature 367 6460 (1994) 295-299
30. Kashanchi F., Khleif S.N., Duvall J.F., Sadaie M.R., Radonovich M.F., Cho M., Martin M.A., Chen S.Y., Weinmann R., and Brady J.N. Interaction of human immunodeficiency virus type 1 Tat with a unique site of TFIID inhibits negative cofactor Dr1 and stabilizes the TFIID-TFIIA complex. J. Virol. 70 8 (1996) 5503-5510
31. Kato H., Sumimoto H., Pognonec P., Chen C.H., Rosen C.A., and Roeder R.G. HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors. Genes Dev. 6 4 (1992) 655-666
32. Kim Y.K., Bourgeois C.F., Isel C., Churcher M.J., and Karn J. Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol. Cell. Biol. 22 13 (2002) 4622-4637
33. Kosco-Vilbois M.H. A mightier mouse with human adaptive immunity. Nat. Biotechnol. 22 6 (2004) 684-685
34. Laspia M.F., Rice A.P., and Mathews M.B. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59 2 (1989) 283-292
35. Malumbres M., Hunt S.L., Sotillo R., Martin J., Odajima J., Martin A., Dubus P., Ortega S., and Barbacid M. Driving the cell cycle to cancer. Adv. Exp. Med. Biol. 532 (2003) 1-11
36. Marciniak R.A., Calnan B.J., Frankel A.D., and Sharp P.A. HIV-1 Tat protein trans-activates transcription in vitro. Cell 63 4 (1990) 791-802
37. Marciniak R.A., and Sharp P.A. HIV-1 Tat protein promotes formation of more-processive elongation complexes. EMBO J. 10 13 (1991) 4189-4196
38. Mukerjee R., Sawaya B.E., Khalili K., and Amini S. Association of p65 and C/EBPbeta with HIV-1 LTR modulates transcription of the viral promoter. J. Cell. Biochem. 100 5 (2007) 1210-1216
39. Nekhai S., Shukla R.R., and Kumar A. A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity. J. Virol. 71 10 (1997) 7436-7441
40. Nekhai S., Shukla R.R., Fernandez A., Kumar A., and Lamb N.J. Cell cycle-dependent stimulation of the HIV-1 promoter by Tat-associated CAK activator. Virology 266 2 (2000) 246-256
41. Nekhai S., Zhou M., Fernandez A., Lane W.S., Lamb N.J., Brady J., and Kumar A. HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem. J. 364 Pt 3 (2002) 649-657
42. Parada C.A., and Roeder R.G. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 384 6607 (1996) 375-378
43. Pumfery A., Deng L., Maddukuri A., de la Fuente C., Li H., Wade J.D., Lambert P., Kumar A., and Kashanchi F. Chromatin remodeling and modification during HIV-1 Tat-activated transcription. Curr. HIV Res. 1 3 (2003) 343-362
44. Richter S., Ping Y.H., and Rana T.M. TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc. Natl. Acad. Sci. U. S. A. 99 12 (2002) 7928-7933
45. Roebuck K.A., Rabbi M.F., and Kagnoff M.F. HIV-1 Tat protein can transactivate a heterologous TATAA element independent of viral promoter sequences and the trans-activation response element. Aids 11 2 (1997) 139-146
46. Schmidtmayerova H., Nuovo G.J., and Bukrinsky M. Cell proliferation is not required for productive HIV-1 infection of macrophages. Virology 232 2 (1997) 379-384
47. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., and Manz M.G. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304 5667 (2004) 104-107
48. Veschambre P., Simard P., and Jalinot P. Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo. J. Mol. Biol. 250 2 (1995) 169-180
49. Watanabe S., Ohta S., Yajima M., Terashima K., Ito M., Mugishima H., Fujiwara S., Shimizu K., Honda M., Shimizu N., and Yamamoto N. Humanized NOD/SCID/IL2R{gamma}null mice transplanted with hematopoietic stem cells under non-myeloablative condition show prolonged lifespans and allow detailed analysis of HIV-1 pathogenesis. J. Virol. 81 23 (2007) 13259-13264
50. Watanabe S., Terashima K., Ohta S., Horibata S., Yajima M., Shiozawa Y., Dewan M.Z., Yu Z., Ito M., Morio T., Shimizu N., Honda M., and Yamamoto N. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 109 1 (2007) 212-218
51. Wei P., Garber M.E., Fang S.M., Fischer W.H., and Jones K.A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92 4 (1998) 451-462
52. Yang X., Gold M.O., Tang D.N., Lewis D.E., Aguilar-Cordova E., Rice A.P., and Herrmann C.H. TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc. Natl. Acad. Sci. U. S. A. 94 23 (1997) 12331-12336
53. Yu L., Loewenstein P.M., Zhang Z., and Green M. In vitro interaction of the human immunodeficiency virus type 1 Tat transactivator and the general transcription factor TFIIB with the cellular protein TAP. J. Virol. 69 5 (1995) 3017-3023
54. Zhang L., Kovalev G.I., and Su L. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 109 7 (2007) 2978-2981
55. Zhou M., Deng L., Lacoste V., Park H.U., Pumfery A., Kashanchi F., Brady J.N., and Kumar A. Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription. J. Virol. 78 24 (2004) 13522-13533
56. Zhu Y., Pe'ery T., Peng J., Ramanathan Y., Marshall N., Marshall T., Amendt B., Mathews M.B., and Price D.H. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes. Dev. 11 20 (1997) 2622-2632